Prof. Dr. Raphael Mechoulam, born 1930 and up till now living in Israel, started reading on cannabis and doing some limited amount of work on it in 1962. Since then his work and achievements are limitless. He has published more than 350 scientific articles.
He was the discoverer of the entourage effect. The entourage effect results when the many components within the cannabis plant interact with the human body to produce a stronger influence than any one of those components alone – it’s a synergistic effect.
Mechoulam compared cannabinoids with a variety of active substances with cannabinoids in which these substances were isolated and purified. He concluded that the various components in cannabinoids interacted positively and gave this effect the name entourage effect.
Please read more about this topic under “Entourage effect”.
Professor Mechoulam was also the discoverer of the endocannabinoid system (ECS) in the early sixties. Although there is evidence that cannabinoids have been used for their medicinal properties since the Stone Age, it was in the 21st century that Professor Mechoulam isolated and identified the psychoactive cannabinoid tetrahydrocannabinol (THC). Previously he and his team had identified the chemical structure of cannabidiol (CBD).
The endocannabinoid system is a body-specific system that consists of a group of endogene cannabinoid receptors in the brain and in the entire central and peripheral nervous system of the body. The ECS has a very important function in our body.
Please read more about this topic under “Endocannabinoid system (ECS)”.
Mechoulam was the first to isolate Δ9-tetrahydrocannabinol, known as THC. THC is the most common cannabinoid and is responsible for emitting psychoactive effects.
Mechoulam has also successfully illustrated and isolated the second most common (non-psychoactive) cannabinoid: cannabidiol, known as CBD. The apparent medical efficacy of CBD as an antipsychotic and potential ingredient in the treatment of chronic pain and epileptic seizures surprised Mechoulam.
Another research project initiated by Mechoulam led to the isolation of the first described endocannabinoid anandamide which was isolated and characterized by two of his postdoctoral researchers, Hanus and Devane.
Anandamide is our natural cannabis in our body that affects our cannabis receptors CB1 and CB2. In addition, it influences the vanilloid receptor, an important receptor for pain perception. Receptors are literally recipients of messages, signals.
Next to anandamide, 2-arachidonoylglycerol (2-AG) was the second endocannabinoid discovered by Mechoulam and his student Shimon Ben-Shabat. 2-AG is present at relatively high levels in the central nervous system. Although 2-AG was a known chemical compound, its occurrence in mammals and its affinity for the cannabinoid receptors were first described in 1994.
Professor Mechoulam is still doing pioneering research in Israel to this day. In Israel it is quite normal to restore both the physical and mental balance in the body through cannabinoids.
Professor Mechoulam’s nickname is “Father of the Endocannabinoid system”.
Watch the video “The Scientist (2015) Medical Marijuana: Studying for a higher purpose – Prof. Dr. Raphael Mechoulam”
In 2016 the Medicinal Genomics and Courtagen Life Sciences announced that Dr. Raphael Mechoulam, cannabis research pioneer and the “Father of Marijuana Research,” would receive the Lifetime Achievement Award at CannMed 2016.
This conference was the first annual Personalized Cannabinoid Medicine Conference held at the Harvard School of Medicine April 10-11, 2016. The conference featured internationally recognized thought leaders, scientists, physicians, and advocates working to advance research into the endocannabinoid system and cannabinoid therapeutics.
Dr. Mechoulam was honored for the significant contributions he made to medical science from his lifetime of work in cannabis research.
In 1963 he elucidated the structure of cannabidiol (CBD), one of the most medically relevant compounds found in cannabis.
Shortly thereafter, he isolated and elucidated the structure of the active component of cannabis, tetrahydrocannabinol (THC) in 1964.
Almost 3 decades later, in 1992 and 1995, he isolated and identified the endogenous cannabinoids, anandamide and 2-AG, which together with specific receptors form the endocannabinoid system – a major endogenous biochemical system found in the brain and periphery that is involved in a wide range of physiological functions.
Find more information in the section “Prof. Dr. Raphael Mechoulam”.
Sources: European Journal of Internal Medicine; US National Library of Medicine
There are many companies in Europe that use industrial hemp as a natural source for the production of CBD extracts and isolates.
Renviden CBD products come from the industrial hemp plant Sativa L., which contains a lot of CBD and little THC. The percentage of THC is even under the Dutch Law’s maximum of 0,2%.
At the moment governments around the world have the legalization of (medical) cannabis or the flexibilization of current legislation on the agenda. Renviden closely follows the developments and progress and find it important to share this with her customers.
Below you will find an overview of various studies conducted by reputable institutes and organizations related to CBD and its effect on various diseases and conditions.
Click below on the link of your choice for English scientific research. You will also find more publications of scientific research on this website under Disease / Conditions.
- Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly, 2018
- Cannabinoid Delivery Systems for Pain and Inflammation Treatment, 2018
- The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy, 2017
- Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy, 2017
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial, 2017
- Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells, 2016
- GPR55 – a putative “type 3” cannabinoid receptor in inflammation, 2016
Below you’ll find an overview of various studies conducted by reputable institutes and organizations related to CBD and its effect on various diseases and conditions.
Although cannabis plants all come from the same family, there’s a significant difference.
There are plants that contain a lot of THC (tetrahydrocannabinol) and little CBD (cannabidiol). Industrial hemp plants on the other hand have no or hardly any (psychoactive) THC but a lot of (non-psychoactive) CBD.
Renviden products come from the industrial hemp plant Cannabis Sativa L., which contains a lot of CBD and very little THC. The percentage of THC is even under the Dutch Law’s maximum of 0,2%.
At the moment governments around the world have the legalization of (medical) cannabis or the flexibilization of current legislation on the agenda.
Renviden closely follow these developments and progress and find it important to share this with her customers.
Click on the link of your choice for English scientific research. Sources: US National Institute of Health (NIH), US National Library of Medicine (NLM), US National Center for Biotechnology Information (NCBI), European journal of internal medicine (EJINME).
- Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment 2016
- Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis 2018
- Neurological Aspects of Medical Use of Cannabidiol 2017
- Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study 2016
- Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice 2014
- Cannabidiol as a Potential Treatment for Anxiety Disorders 2015
- Evidences for the Anti-panic Actions of Cannabidiol 2017
- Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis 2017
- Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis 2016
- Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma 2015
- A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study 2017
- Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor 2018
- Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke 2017
- Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer 2018
- Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines 2018
- Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis 2018
- Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex 2018
- Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract 2018
- Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans 2018
- Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science 2018
- Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort 2018
- Cannabidiol to Improve Mobility in People with Multiple Sclerosis 2018
- Neurological Aspects of Medical Use of Cannabidiol 2017
- Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay 2018
- Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain 2018
- Neurological Aspects of Medical Use of Cannabidiol 2017
- Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial 2014
Stress; Posttraumatic Stress Disorder
EACH BODY IS UNIQUE
Each body is different. Each body’s fat percentage is different. Each body responds differently. So basically, there is no one size that fits all.
It takes time for CBD to build up in your system to have a full effect. Some people respond immediately and for some people it takes longer to feel the effect.
In the beginning it’s just looking for the right dose. So take your time, be patient and start out low, for example 1 or 2 mg / drops a day.
When after some time you want to double it, you can simply double your doses in one intake or take one dose in the morning and one in the evening. Of course it depends on what you are using it for.
For example if you’re using it for a good night sleep you might want to double the dose in the evening. This will have more effect than taking a few doses during the day.
But for other purposes, for example treatment of pain, it might be better to spread the CBD intake throughout the day. This also gives your body a chance to better absorb it and to stay in your system. By doing so, you’re constantly feeding your body with these nutrients.
Note: Although there is no general dosage because each body is unique, the EIHA (European Industrial Hemp Organization) recommends a maximum dosage of 160 mg per day for adults.
Remember that the effects of CBD may be non-linear, meaning too much of it may be counterproductive and produce opposite effects of what you’re looking for. Also, your body can only absorb a certain amount of CBD at a time.
Always bear in mind that each body is different. Each body is unique. Take the time to find out what is the best dose for you.
FREQUENTLY ASKED QUESTIONS
What does Renviden mean?
Renviden comes from Danish.
Ren = pure
Viden = knowledge
Renviden is a Dutch company that collaborates with its Danish partner Plantine.
What is the difference between weed, hemp?
Although hemp and weed come from the same cannabis family, there are many differences. Cannabis contains a high concentration of THC, the psychoactive component of the plant. Hemp contains a high concentration of CBD, is not psychoactive and has a very low THC content.
THC above 0.2% is forbidden in the Netherlands. CBD oil is tolerated in the Netherlands under the Opium Act, provided that it is produced from EU permitted fiber hemp species and contains no more than 0.2% THC.
What is CBD oil?
CBD stands for cannabidiol, an important component of the cannabis plant. Cannabidiol is better known as CBD oil that can be used as a dietary supplement. CBD oil can help in maintaining the balance in body and mind.
What are cannabinoids?
Cannabinoids are a group of substances that occur naturally in the cannabis plant. But they also occur in the human body: the so-called endocannabinoids.
There are hundreds of cannabinoids, but the best known are THC, the psychoactive substance and CBD, the non-psychoactive substance known for its beneficial effects.
What is the difference between CBD and THC?
CBD stands for cannabidiol and is a non-psychoactive component of the hemp plant.
THC stands for tetrahydrocannabinol and is the psychoactive component of the hemp plant.
The CBD products from Renviden come from the industrial hemp plant Sativa L. which contains a lot of CBD and contains other healthy components of the hemp plant and little THC.
Can I get high from CBD oil?
The percentage of THC, the psychoactive component of the hemp plant, in the CBD products of Renviden is in accordance with the legally permitted maximum and is so low that it is not possible to get high or stoned.
What does CBD help for?
Particularly due to the therapeutic effect of certain substances of CBD, these cannabinoids have proven to be very interesting for scientists because of the wide range of applications and treatment of various disorders.
Unfortunately, we at Renviden are not allowed to make medical claims, but there is a lot of information on the internet and in our Knowledge Center we refer to public publications.
Is CBD oil legal?
THC above 0.2% is forbidden in the Netherlands. CBD oil is tolerated in the Netherlands under the Opium Act, provided that it is produced from EU permitted fiber hemp species and contains no more than 0.2% THC. The products of Renviden meet this standard.
What does bioavailability mean?
Bioavailability is the absorption of active substances by the body. They pass through the intestinal wall and enter the targeted areas of the body through the bloodstream. A high bioavailability is very important, because otherwise the substances do not end up in the right place in the body.
The bioavailability or part of an active substance that is absorbed into the gastrointestinal tract and can be used by the body, is influenced by many different factors. For example the chemical form in which the active substance occurs, the compounds that are entered into with other substances and individual factors.
The CBD oil from Renviden is composed of a protein in which the full spectrum micronized flower- and leaves particles are micro-encapsulated. Because of the fact that these particles are protected by proteins, the effect is up to 52 times higher compared to traditional non-encapsulated CBD products.
What does endocannabinoid system mean?
Endogen means “from the inside”. The endocannabinoid system is your body’s own cannabinoid system. This consists of a group of endogenous cannabinoid receptors (receptors) in the brain and in the entire central and peripheral nervous system of your body.
The endocannabinoid system has a very important function in your body. It ensures that your health is in balance. In case of imbalance it may be good to use the full spectrum CBD oil from Renviden.
What does full spectrum mean?
CBD is one of the natural components of the industrial hemp plant. These and the other vegetable cannabinoids THC, THCA, CBDA, CBG, CBGA, CBN, in combination with terpenes and minerals, provide the benefits of a full spectrum CBD product. Full spectrum keeps the full properties of the hemp plant intact. By retaining all plant-based components, the full spectrum CBD from Renviden benefits from the synergistic properties between the components, the so-called entourage effect.
What does microencapsulation mean?
Encapsulation is a process in which small particles of core products are packaged in a matrix to form microcapsules. During the Renviden production full spectrum micronized flower- and dried leave particles are micro-encapsulated in pea proteins. All active substances are encased in a matrix that not only protects against adverse environmental factors and potentially dangerous processes, but preserves healthy cannabinoids and all other active substances in the product for optimal effect.
Can I take my CBD product abroad?
Despite the fact that there is a THC percentage in the CBD products of Renviden that is in accordance with the tolerance policy of the Dutch government, we do not recommend taking your product abroad. Not all customs officials are aware of the regulations of the different countries.
Can I claim CBD products from my health insurance company?
Unfortunately not yet in the Netherlands.
What does entourage effect mean?
When multiple components of the hemp plant work together, they have a greater effect on the body than if one of those components were used alone. This synergistic phenomenon is known as the entourage effect.
It creates connections with different positive effects on the balance in body and mind. This balance is internally controlled by the endocannabinoid system (ECS), the body’s own cannabinoid system.
What is the dosage?
There is no “one size fits all” because each body is unique, everyone’s fat percentage is different and each body responds differently. It takes time to fully build up CBD in your system. Some people react immediately and for some people it takes longer to feel the effect.
In the beginning it is just looking for the right dose. So take the time to find out what the best dose is for you. Start low, for example, 1 or 2 mg / drops per day or one 6 mg CBD capsule per day and switch to the 3 mg capsules as a maintenance dose after one month.
Although there is no general dosage because each body is unique, the EIHA (European Industrial Hemp Organization) recommends a maximum dosage of 160 mg per day for adults.
How do I store my CBD product?
Keep your CBD products dry, closed and stored at room temperature. Keep out of reach of young children.
For more information, visit the Knowledge Center.